Genotype-phenotype correlation of renal lesions in the tuberous sclerosis complex

Yoshinari Muto; Hitomi Sasaki; Makoto Sumitomo; Hidehito Inagaki; Maki Kato; Takema Kato; Shunsuke Miyai; Hiroki Kurahashi; Ryoichi Shiroki

doi:10.1038/s41439-022-00181-1

Genotype-phenotype correlation of renal lesions in the tuberous sclerosis complex

Hum Genome Var. 2022 Feb 10;9(1):5. doi: 10.1038/s41439-022-00181-1.

Authors

Affiliations

¹ Department of Urology, School of Medicine, Fujita Health University, Toyoake, Japan. naru.muto@gmail.com.
² Department of Urology, School of Medicine, Fujita Health University, Toyoake, Japan.
³ Division of Molecular Genetics, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Aichi, 470-1192, Japan.

^# Contributed equally.

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disease caused by loss-of-function mutations in either of two tumor suppressor genes, TSC1 and TSC2. These mutations lead to the growth of benign tumors and hamartomas in many organs, including those of the central nervous system, the skin, and the kidneys. To investigate the genotype-phenotype correlation, we performed sequence analysis of the TSC1/2 genes using next-generation sequencing. We classified 30 patients with TSC whose pathogenic variants were identified into two groups: those with mutations producing premature termination codons (PTCs) and those with missense mutations. Then, we compared the phenotypes between the two groups. Patients with a PTC were significantly more likely to manifest the major symptoms of the diagnostic criteria than those without a PTC (P = 0.035). The frequencies of subependymal nodules (P = 0.026), cortical tubers (P = 0.026), and renal cysts (P = 0.026) were significantly higher in PTC-containing variants than in cases without a PTC. When the analyses were limited to renal angiomyolipoma (AML) cases with TSC2 mutations, there was no difference in tumor size between cases with and without a PTC. However, the cases with a PTC showed a trend toward disease onset at a younger age and multiple tumors, and bilateral disease was observed in their AML lesions. TSC patients with PTC-producing mutations might potentially manifest more severe TSC phenotypes than those with missense mutations. A larger-scale study with appropriate samples deserves further investigation.